|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Neither SAGE nor Northern analysis revealed the presence of HC gp-39 mRNA in the glioblastoma cell line, thus the detection of increased quantities of this mRNA in GBMs may be associated with activated macrophages.
|
12957359 |
2003 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 expression is strongly elevated in serum and biopsy material from glioblastomas patients.
|
15771622 |
2005 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
YKL-40 expression was also compared with genetically defined subsets of glioblastoma by assessing epidermal growth factor receptor amplification and loss at chromosome 10q, two of the common recurring aberrations in these tumors, using fluorescent in situ hybridization.
|
15867231 |
2005 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 expression was also compared with genetically defined subsets of glioblastoma by assessing epidermal growth factor receptor amplification and loss at chromosome 10q, two of the common recurring aberrations in these tumors, using fluorescent in situ hybridization.
|
15867231 |
2005 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma.
|
18092325 |
2008 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Serum YKL-40 and bone marrow angiogenesis in multiple myeloma.
|
19089918 |
2009 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Taken together our data suggest that the variant allele (-131C-->G) of CHI3L1 promoter has no significant impact on survival and is not a prognostic factor for glioblastoma.
|
19255724 |
2009 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High YKL-40 protein expression assessed by immunohistochemistry is found in breast carcinomas associated with short disease-free survival and in glioblastomas with increased resistance to radiotherapy and decreased overall survival.
|
19347297 |
2009 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The objective of this study was to evaluate, in a series of 43 pediatric high-grade gliomas (21 anaplastic astrocytoma WHO grade III and 22 glioblastoma WHO grade IV), the prognostic value of histological grading and expression of p53 and YKL-40.
|
20174854 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 expression was higher in GBMs than AOs (P < 0.0001) and among GBMs, YKL-40 expression was lower in tumors with either EGFR amplification (P = 0.005) or elevated EGFR expression (P = 0.001).
|
20224722 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The YKL-40 coding chitinase 3-like 1 gene is 1 of the most overexpressed genes in human glioblastomas.
|
20499402 |
2010 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Resveratrol represses YKL-40 expression in human glioma U87 cells.
|
21029458 |
2010 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
YKL-40 up-regulated VEGF expression in glioblastoma cell line U87, and both YKL-40 and VEGF synergistically promote endothelial cell angiogenesis.
|
21385870 |
2011 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Although YKL-40 expression is up-regulated in glioblastoma multiforme, its regulation and functions in nontransformed cells of the central nervous system are widely unexplored.
|
21953450 |
2011 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Fitting models with and without YKL-40 highlights a subgroup of patients who have glioblastoma (GBM) diagnosis but appear to have better prognosis than the typical GBM patient.
|
22495652 |
2012 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this paper, the authors' goal was to evaluate the prognostic value of YKL-40 expression as a prognostic factor for glioblastomas and to compare its validity to the already known MGMT.
|
22655594 |
2012 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, YKL‑40 may be a novel key molecule in addition to MGMT, that is responsible for TMZ resistance in glioblastoma cell lines and could be a new target to overcome TMZ resistance in recurrent glioblastomas in the future.
|
24842123 |
2014 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
YKL-40 staining in situ was more abundant in glioblastoma tissue than in anaplastic astrocytoma, with the lowest level in normal brain tissue.
|
25629266 |
2014 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM.
|
26212701 |
2016 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Meta-analysis of those studies showed that high YKL-40 expression was associated with worse overall survival in glioblastoma patients (HR = 1.46, 95%CI 1.33-1.61, P < 0.001).
|
27090900 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Findings presented in our study showed that increased mRNA level of CHI3L1 could be associated with the progression of astrocytoma and poor patient survival not only for glioblastoma, but for lower grade astrocytoma tumors as well.
|
27121858 |
2016 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Stepwise multivariate Cox proportional hazards models were used, and the prognostic factors to significantly impact OS were: PFS < 54 weeks (HR: 5.86; CI: 3.02-11.33; p = 0.00); radiotherapy (HR: 0.34; CI: 0.18-0.60; p = 0.00); radio- and chemotherapy (HR: 0.05; CI: 0.03-0.10; p = 0.0), and YKL-40+ GBs (HR: 1.61; CI: 1.28-2.31; p = 0.01).
|
27179219 |
2016 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Phospho-c-Jun activation by Anisomycin treatment in primary glioblastoma-derived cells attenuates the aggressive features of mesenchymal glioblastomas and leads to promoter methylation and downregulation of key mesenchymal genes (CD44, MMP9 and CHI3L1).
|
28036297 |
2017 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Previous studies have demonstrated that glioblastoma stem cells give rise to endothelial cells through an YKL-40 influence.
|
28430288 |
2017 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab.
|
29467925 |
2018 |